Toggle light / dark theme

Glaucoma is a surprisingly common condition that can have serious consequences if it goes untreated. Understanding the importance of early detection, a team of engineers and ophthalmologists in Australia has developed a novel approach using AI to diagnose glaucoma that can yield results in just 10 s.


Have you ever experimented with food dye? It can make cooking a lot more fun, and provides a great example of how two fluids can mix together well—or not much at all.

Add a small droplet in water and you might see it slowly dissolve in the larger liquid. Add a few more drops and perhaps you’ll see a wave of color spread, the colored droplets spreading and breaking apart to diffuse more thoroughly. Add a spoon and begin stirring quickly, and you’ll probably find that the water fully changes color, as desired.

Researchers at the USC Viterbi School of Engineering, led by Ivan Bermejo-Moreno, assistant professor of aerospace and mechanical engineering, studied a similar phenomenon with gases at high speeds, with an eye toward more efficient mixing to support supersonic scramjet engines. In the study, published in Physics of Fluids, USC Viterbi Ph.D. Jonas Buchmeier, along with Xiangyu Gao (USC Viterbi Ph.D. ‘20) and former visiting M.Sc. student Alexander Bußmann (Technical University Munich), developed a novel tracking method that zoomed in on the fundamentals of how mixing happens. The study helps understand, for example, how injected fuel interacts with the surrounding oxidizers (air) in the engine to make it operate optimally, or how interstellar gases mix after a supernova explosion to form new stars. The method focuses on the geometric and physical properties of the turbulent swirling motions of gases and how they change shape over time as they mix.

Professor Norikazu Ichihashi and his colleagues at the University of Tokyo have successfully induced gene expression from a DNA, characteristic of all life, and evolution through continuous replication extracellularly using cell-free materials alone, such as nucleic acids and proteins for the first time.

The ability to proliferate and evolve is one of the defining characteristics of living organisms. However, no artificial materials with these characteristics have been created. In order to develop an artificial molecular system that can multiply and evolve, the information (genes) coded in DNA must be translated into RNA, proteins must be expressed, and the cycle of DNA replication with those proteins must continue over a long period in the system. To date, it has been impossible to create a reaction system in which the genes necessary for DNA replication are expressed while those genes simultaneously carry out their function.

The group succeeded in translating the genes into proteins and replicating the original circular DNA with the translated proteins by using a circular DNA carrying two genes necessary for DNA replication (artificial genomic DNA) and a cell-free transcription-translation system. Furthermore, they also successfully improved the DNA to evolve to a DNA with a 10-fold increase in replication efficiency by continuing this DNA replication cycle for about 60 days.

By adding the genes necessary for transcription and translation to the artificial genomic DNA developed by the group, it could be possible to develop artificial cells that can grow autonomously simply by feeding them low-molecular-weight compounds such as amino acids and nucleotides, in the future. If such artificial cells can be created, we can expect that useful substances currently produced using living organisms (such as substances for drug development and food production) will become more stable and easier to control.

This research has been led by Professor Norikazu Ichihashi, a research director of the project “Development of a self-regenerative artificial genome replication-transcription-translation system” in the research area “Large-scale genome synthesis and cell programming” under the JST’s Strategic Basic Research Programs CREST (Team type). In this research area, JST aims to elucidate basic principles in relation to the structure and function of genomes for the creation of a platform technology for the use of cells.

The pandemic brought about a change in the way people look at technology. 2021 proves to be the development of a new era of technology where AI is at the core.

According to McKinsey’s Global Survey on artificial intelligence (AI) 2020, organizations are using AI as a tool for generating value in the form of revenues. Some executives have even observed that implementing AI has brought about a change of 20% in the organizations’ earnings. The COVID-19 pandemic has accelerated the concept of ‘all things digital’, and these companies plan to invest more in AI.

Informed consent not something we hear a lot about these days, which is kind of odd, given all the drugs our government currently insists that we take and how often those very same legal concepts are invoked for aboriginal rights and sexual assault cases.


“Informed consent” is a well understood legal doctrine in healthcare, requiring the healthcare provider (traditionally a doctor) to educate patients about the risks, benefits, and alternatives of any given recommended procedure or intervention, allowing the patient to make informed and “voluntary” decisions about whether to undergo the procedure.

No, it’s not from a science fiction movie or from an episode of a popular kid’s television show. It’s real life. Researchers, in a proof-of-concept study, have made fish-shaped microrobots that are guided with magnets to cancer cells, where a pH change triggers them to open their mouths and release their chemotherapy cargo.

Scientists have previously made microscale (smaller than 100 µm) robots that can manipulate tiny objects, but most can’t change their shapes to perform complex tasks, such as releasing drugs. Some groups have made 4D-printed objects (3D-printed devices that change shape in response to certain stimuli), but they typically perform only simple actions, and their motion can’t be controlled remotely.

In a step toward biomedical applications for these devices, Jiawen Li, Li Zhang, Dong Wu and colleagues wanted to develop shape-morphing microrobots that could be guided by magnets to specific sites to deliver treatments. Because tumors exist in acidic microenvironments, the team decided to make the microrobots change shape in response to lowered pH.

The vaccine candidate was originally developed by the Israel Institute for Biological Research (IIBR), which operates under the auspices of the Prime Minister’s Office and works closely with the Defense Ministry.

The institute’s strategic and technical capabilities are shrouded in secrecy, but this week, The Jerusalem Post gained access to new data that show BriLife could be more effective against mutations and confer lasting immunity.


The Israeli vaccine could potentially address COVID better than other technologies, according to the CEO of NeuroRx.

Oramed Pharmaceuticals, the developer of the Oravax oral COVID-19 vaccine candidate, has announced a partnership with Mexico’s Genomma Lab Internacional to help fast-track a Phase II clinical trial and gain emergency use authorization in the Latin American country.


Only about 58% of Mexico’s population has been jabbed with one dose of a coronavirus vaccine, averaging around 4,500 new cases per day.

The Biden administration is expected to announce this week it is purchasing 10 million courses of treatment Pfizer’s covid pill, a multibillion dollar investment in a medication that officials hope will help change the trajectory of the pandemic by staving off many hospitalizations and deaths, according to two people with knowledge of the transaction.

-call me Nostradamus, but I called this.


Officials see Pfizer’s pill, and another by Merck, as potential gamechangers to tame the pandemic.